// App-Quantinova.ai

: A high-risk airway mycobiome characterises frequent COPD exacerbators

Researchers

Presenter

  • Pei Yee Tiew

Principal Investigators

  • Alison Dicker

  • Holly R Keir

  • Mau Ern Poh

  • Sze Lei Pang

  • Sri Anusha Matta

  • Branden Qi Yu Chua

  • Huiying Xu

  • Mariko Siyue Koh

  • Augustine Tee

  • John Arputhan Abisheganaden

  • Fook Tim Chew

  • Bruce E Miller

  • Ruth Tal-Singer

  • James D. Chalmers

  • Sanjay H Chotirmall

Medical Centers

  • Lee Kong Chain School of Medicine, Nanyang Technical University, Singapore, Singapore, Singapore

  • University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom

  • University Malaya Medical Center, Kuala Lumpur, Malaysia

  • Department of Pathology, National University of Singapore, Singapore, Singapore

  • Department of Respiratory and Critical Medicine, Singapore General Hospital, Singapore, Singapore.

  • Department of Respiratory and Critical Medicine, Singapore General Hospital, Singapore, Singapore.

  • Department of Respiratory and Critical Medicine, Singapore General Hospital, Singapore, Singapore.

  • GlaxoSmithKline , Pennsylvania, United States of America

Locations

  • Singapore

  • United Kingdom

  • Malaysia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Glaxosmithkline & British Lung Foundation

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved